describ
metagenom
nextgener
sequenc
mng
human
coronaviru
patient
aml
persist
upper
respiratori
symptom
underw
hematopoiet
cell
transplant
hct
mng
reveal
delet
compris
near
entireti
gene
minor
allel
variant
detect
suggest
mix
infect
part
prehct
condit
regimen
patient
receiv
myeloabl
treatment
cyclophosphamid
gy
total
bodi
irradi
iter
sequenc
rtpcr
confirm
four
respiratori
sampl
peritranspl
period
reveal
precondit
strain
contain
intact
gene
delet
strain
appear
condit
persist
period
sequenc
repres
one
largest
genom
delet
detect
human
rna
viru
describ
largescal
viral
mutat
associ
myeloabl
hct
coronavirus
positivestrand
rna
virus
larg
genom
rang
size
kb
although
much
attent
paid
epidem
potenti
high
mortal
rate
middl
east
respiratori
syndrom
coronaviru
sever
acut
respiratori
syndrom
coronaviru
coronavirus
common
human
coronavirus
hcov
includ
virus
hcov
alphacoronavirus
genom
length
kb
hcov
betacoronavirus
genom
length
around
kb
studi
conduct
genom
evolut
common
hcov
speci
hcov
enact
major
burden
hematopoiet
cell
transplant
hct
patient
cumul
incid
hcov
infect
among
hct
day
transplant
hcov
hct
patient
associ
prolong
shed
median
durat
week
condit
regimen
hct
usual
consist
chemotherapi
irradi
may
induc
genom
alter
treatmentrel
myeloid
leukemia
wellknown
associ
radiat
therapi
chemotherapeut
agent
cyclophosphamid
describ
gener
larg
delet
rna
viru
tempor
associ
myeloabl
condit
regimen
hct
viru
analyz
femal
acut
myelogen
leukemia
aml
present
hematopoet
cell
transplant
previou
year
undergon
four
cycl
chemotherapi
gclam
gcla
cytarabin
decitabineprim
mec
prior
month
bone
marrow
evalu
show
blast
flow
cytometri
normal
cytogenet
day
day
prior
transplant
found
infect
coronaviru
cycl
threshold
ct
persist
ct
day
fig
base
patient
risk
relaps
leukemia
rel
rariti
hcov
pneumon
decis
made
continu
hct
despit
ongo
viral
shed
day
receiv
cyclophosphamid
mgkg
day
receiv
dose
twicedaili
gy
total
bodi
irradi
cumul
dose
gy
fig
signific
drug
patient
receiv
time
period
includ
acyclovir
granisetron
micafungin
voriconazol
sulfamethoxazoletrimethoprim
mismatch
unrel
donor
peripher
blood
stemcel
transplant
perform
day
throughout
hcov
infect
patient
mild
nasal
congest
never
requir
supplement
oxygen
cours
complic
bacteremia
day
day
transplant
thought
due
grade
mucos
discharg
day
four
nasal
swab
sampl
fourweek
period
avail
patient
qrtpcr
cycl
threshold
ct
recov
fourweek
period
compar
rang
tabl
percent
total
read
map
hcov
rang
consist
low
concentr
viru
found
qrtpcr
tabl
mng
day
posttranspl
specimen
reveal
larg
delet
encompass
nucleotid
orf
gene
fig
averag
coverag
across
viral
genom
repeat
librari
prepar
specimen
demonstr
delet
delet
found
whether
map
hcov
refer
genom
de
novo
assembl
read
recov
within
area
delet
suggest
presenc
viral
popul
entir
contain
genom
delet
mng
day
day
specimen
patient
reveal
complet
intact
fig
larg
delet
consensu
variant
observ
hcov
consensu
genom
recov
day
day
day
specimen
map
read
day
day
day
sampl
day
consensu
genom
reveal
two
minor
allel
variant
reach
allel
frequenc
consist
allel
frequenc
day
day
sampl
first
g
p
chang
replicas
protein
went
undetect
day
day
specimen
fig
detect
delet
hcov
strain
associ
myeloabl
depict
case
histori
surround
myeloabl
coronaviru
infect
woman
aml
found
infect
hcov
hct
due
patient
advanc
diseas
decis
made
continu
transplant
four
success
hcovposit
nasal
swab
specimen
avail
patient
two
treatment
myeloabl
cyclophosphamid
total
bodi
irradi
two
day
report
rel
hct
b
coverag
plot
mng
read
map
refer
genom
hcov
three
sampl
patient
reveal
gener
delet
gene
addit
delet
code
region
delet
result
frame
shift
result
prematur
stop
codon
amino
acid
refer
genom
stop
codon
primer
bind
site
denot
blue
confirmatori
junction
rtpcr
c
confirmatori
junction
rtpcr
four
avail
hcovposit
nasal
swab
reveal
absenc
delet
myeloabl
presenc
delet
specimen
taken
myeloabl
ntc
templat
control
allel
frequenc
day
specimen
second
maintain
allel
frequenc
day
day
day
specimen
junction
read
across
delet
found
either
day
day
specimen
mng
mng
day
specimen
also
demonstr
delet
coverag
across
genom
consist
rna
degrad
figur
consensu
variant
observ
genom
region
cover
day
specimen
confirmatori
rtpcr
across
orf
gene
demonstr
intact
gene
premyeloabl
specimen
smaller
pcr
product
consist
delet
day
day
postmyeloabl
specimen
fig
deep
sequenc
day
day
pcr
amplicon
reveal
junction
read
day
specimen
map
day
delet
strain
locu
coverag
locu
intact
gene
day
strain
figur
convers
one
pairedend
read
day
specimen
map
delet
portion
gene
locu
day
strain
coverag
locu
day
delet
strain
figur
attempt
cultur
patient
specimen
cell
prove
unsuccess
cpe
visual
patient
four
clinic
sampl
hcov
rna
level
cultur
supernat
undetect
qrtpcr
inocul
viral
growth
appar
posit
control
hcov
atcc
type
strain
figur
describ
metagenom
detect
larg
delet
hcov
strain
tempor
associ
myeloabl
regimen
cyclophosphamid
total
bodi
irradi
hct
patient
viru
maintain
viral
load
week
period
clonal
day
transplant
suggest
replic
compet
vivo
major
consensu
variant
hcov
genom
aros
sampl
period
one
minor
variant
aros
day
specimen
present
earlier
specimen
anoth
minor
variant
maintain
similar
allel
frequenc
throughout
sampl
period
rate
singl
nucleotid
variant
evolut
consist
molecular
clock
hcov
studi
found
hcov
genom
variant
aros
first
month
infect
abil
viru
persist
vivo
despit
near
complet
loss
suggest
accessori
gene
complet
dispens
hcov
replic
may
outcompet
wildtyp
viru
certain
condit
inde
hcov
type
strain
contain
delet
split
alpaca
alphacoronaviru
contain
insert
also
disrupt
read
frame
meanwhil
coronavirus
includ
known
hcov
clinic
strain
contain
intact
first
detect
nonintact
hcov
associ
human
infect
function
alphacoronavirus
unknown
protein
sequenc
show
signific
align
protein
protein
data
bank
hhpred
hcov
type
strain
suggest
viroporin
possess
ion
channel
activ
interestingli
replac
hcov
type
strain
renilla
luciferas
result
viral
replic
vitro
compar
wildtyp
strain
consist
vivo
data
unlik
requir
replic
taken
togeth
data
suggest
would
make
poor
antivir
target
human
coronavirus
mani
potenti
mechan
develop
delet
exist
chemotherapi
andor
irradi
could
directli
toxic
coronaviru
genom
cyclophosphamid
wellknown
clastogen
recent
associ
increas
develop
singl
nucleotid
variat
insert
delet
altern
myeloabl
regim
could
remov
immun
pressur
allow
loss
seem
certain
circumst
delet
could
prove
select
advantag
allel
present
day
specimen
studi
sever
limit
unabl
cultur
patient
hcov
specimen
demonstr
abil
replic
vitro
necessarili
surpris
hcov
usual
cultur
clinic
virolog
lab
viru
present
low
concentr
sampl
also
limit
accur
call
minor
variant
rel
low
coverag
viral
genom
attempt
revers
genet
alphacoronavirus
definit
show
dispens
vitro
replic
although
abil
type
strain
replic
despit
delet
luciferas
gene
replac
experi
describ
consist
possibl
summari
describ
larg
delet
hcov
encompass
almost
entir
gene
tempor
associ
myelobl
littl
known
genom
evolut
hcov
genom
current
avail
ncbi
genbank
similarli
size
nucleotid
delet
previous
found
hepat
viru
patient
receiv
antivir
therapi
studi
also
first
demonstr
microbi
evolut
associ
cyclophosphamid
treatment
irradi
research
chemotherapi
irradi
affect
microbiom
warrant
mng
increasingli
perform
clinic
lab
much
intrigu
biolog
unlock
clinic
specimen
provid
continu
case
sequenc
clinic
microbi
genom
hcov
type
strain
atcc
obtain
use
posit
control
cell
cultur
two
hundr
microlit
patient
nasal
swab
viral
transport
media
mem
inocul
onto
cell
atcc
incub
stationari
rack
min
incub
ml
mem
ad
tube
incub
day
tube
read
cytopath
effect
supernat
store
cultur
supernat
extract
roch
magna
pure
lc
rna
elut
water
ten
microlit
rna
use
qrtpcr
primer
target
hcov
polymeras
gene
qrtpcr
patient
sampl
perform
nasal
swab
viral
transport
extract
pcr
condit
metagenom
nextgener
sequenc
confirmatori
rtpcr
deep
sequenc
mng
perform
describ
previous
briefli
extract
rna
treat
dnase
doubl
strand
cdna
creat
use
random
hexam
superscript
iii
sequenas
thermo
fisher
mng
librari
creat
use
onethird
volum
nexteraxt
reaction
cycl
pcr
amplif
mng
librari
hcov
refer
genom
strain
sequenc
studi
averag
pairwis
nucleotid
ident
major
consensu
genom
mng
call
use
minimum
coverag
read
specimen
also
map
day
consensu
genom
look
minor
variant
aros
treatment
due
low
coverag
minor
variant
call
minimum
allel
frequenc
coverag
trim
invers
due
nextera
artifact
variant
within
nucleotid
end
read
pcr
duplic
confirmatori
gap
junction
rtpcr
perform
rna
extract
use
cycl
follow
manufactur
recommend
condit
tm
c
use
quartervolum
qiagen
one
step
rtpcr
kit
primer
deep
sequenc
day
day
pcr
amplicon
perform
use
ng
pcr
product
purifi
zymo
dna
clean
concentr
volum
kapa
hyperplu
kit
ligat
yshape
adapt
follow
seven
cycl
truseqadapt
dualindex
pcr
amplif
sequenc
perform
use
bp
run
illumina
miseq
day
amplicon
pairedend
read
recov
day
amplicon
pairedend
read
recov
pcr
product
truseqadapt
qualitytrim
use
bbduk
align
intact
delet
allel
present
day
day
consensu
genom
use
geneiou
read
align
gap
mismatch
allow
inform
disclos
case
report
compli
hipaa
privaci
rule
requir
protect
health
inform
patient
provid
written
inform
irbapprov
consent
research
excess
clinic
specimen
sequenc
deposit
ncbi
genbank
strain
name
day
day
day
nonhuman
read
deposit
ncbi
short
read
archiv
access
